Lithium as sole treatment vs placebo
Thyroid dysfunction outcome not available in any study · schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Findings
What do systematic reviews say?
143 questions · 144 findings · 9 reviews
No studies found 41 · 28.5%GRADE not reported 8 · 5.6%Very low 26 · 18.1%Low 31 · 21.5%Moderate 25 · 17.4%High 13 · 9%
Adjunctive lithium + antipsychotics vs placebo/no adjunctive treatment + antipsychotics
Response to treatment clinically relevant response as defined by the authors · schizophrenia
Adjunctive lithium + antipsychotics may leads to higher response to treatment clinically relevant response as defined by the… compared with placebo/no adjunctive treatment + antipsychotics (low certainty).
1 finding from 1 review
- RR 1.81 [1.1, 2.97]10 studies · 396 participantsLow
Adjunctive lithium + antipsychotics vs placebo/no adjunctive treatment + antipsychotics
Acceptability ‐ total dropouts · schizophrenia
It is very uncertain whether adjunctive lithium + antipsychotics changes acceptability of treatment leaving early due to any reason compared with placebo/no adjunctive treatment + antipsychotics (very low certainty).
1 finding from 1 review
- RR 1.89 [0.93, 3.84]11 studies · 320 participantsVery low
Adjunctive lithium + antipsychotics vs placebo/no adjunctive treatment + antipsychotics
> 50% reduction in depressive symptoms · schizophrenia
Adjunctive lithium + antipsychotics showed no clear difference in clinically significant response on depressive symptoms at least 50%… compared with placebo/no adjunctive treatment + antipsychotics (low certainty).
1 finding from 1 review
- RR 1.05 [0.69, 1.58]1 study · 45 participantsLow
Adjunctive lithium + antipsychotics vs placebo/no adjunctive treatment + antipsychotics
Clinically significant response on manic symptoms at least 50% Bech‐Rafaelsen improvement · schizophrenia
Adjunctive lithium + antipsychotics showed no clear difference in clinically significant response on manic symptoms at least 50%… compared with placebo/no adjunctive treatment + antipsychotics (low certainty).
1 finding from 1 review
- RR 1.13 [0.7, 1.82]1 study · 45 participantsLow
Adjunctive lithium + antipsychotics vs placebo/no adjunctive treatment + antipsychotics
Clinically significant response on positive symptoms at least 50% MS improvement · schizophrenia
Adjunctive lithium + antipsychotics showed no clear difference in clinically significant response on positive symptoms at least 50% MS… compared with placebo/no adjunctive treatment + antipsychotics (low certainty).
1 finding from 1 review
- RR 0.84 [0.62, 1.13]1 study · 45 participantsLow
Adjunctive lithium + antipsychotics vs placebo/no adjunctive treatment + antipsychotics
Kidney dysfunction outcome not available in any study · schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Adjunctive lithium + antipsychotics vs placebo/no adjunctive treatment + antipsychotics
Thyroid dysfunction outcome not available in any study · schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Metal-free FDPs (lithium disilicate) vs Metal-ceramic FDPs
Aesthetics · Adults (18 years or older) needing a three-unit fixed dental prosthesis (FDP)
The review found no eligible studies for this question.
1 finding from 1 review
- No data were presented with regard to aesthetics.0 studiesNo studies found
Metal-free FDPs (lithium disilicate) vs Metal-ceramic FDPs
Bridge complications · Adults (18 years or older) needing a three-unit fixed dental prosthesis (FDP)
It is very uncertain whether metal-free FDPs (lithium disilicate) changes bridge complications compared with metal-ceramic FDPs (very low certainty).
1 finding from 1 review
- OR 0.07 [0.01, 0.75]1 study · 22 participantsVery low
Metal-free FDPs (lithium disilicate) vs Metal-ceramic FDPs
Bridge failure · Adults (18 years or older) needing a three-unit fixed dental prosthesis (FDP)
It is very uncertain whether metal-free FDPs (lithium disilicate) changes bridge failure compared with metal-ceramic FDPs (very low certainty).
2 findings from 1 review
- OR 6.86 [0.66, 71.72]1 study · 22 participantsVery low
- OR 9.00 [0.96, 84.50]1 study · 37 participantsVery low
Metal-free FDPs (lithium disilicate) vs Metal-ceramic FDPs
Periodontal/peri-implant status and occlusal wear (secondary outcomes) · Adults (18 years or older) needing a three-unit fixed dental prosthesis (FDP)
The review found no eligible studies for this question.
1 finding from 1 review
- No data were presented for any of the pre-specified secondary outcomes.0 studiesNo studies found
Mood stabilisers vs placebo
Repetition of SH at post‐intervention · self‐harm in adults
It is very uncertain whether mood stabilisers, including antiepileptics and lithium changes repetition of SH by post‐intervention№ of participants: 167(1 RCT) compared with placebo (very low certainty).
1 finding from 1 review
- OR 0.99 [0.33, 2.95]Studies not reportedVery low
Immediate‐release methylphenidate vs lithium
Clinical impression: severity ‐ not reported · adults with ADHD (available evidence for participants aged between 25 to 53 years old)
The review found no eligible studies for this question.
1 finding from 1 review
- Immediate‐release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults 2021 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Immediate‐release methylphenidate vs lithium
Clinical impression: improvement‐ not reported · adults with ADHD (available evidence for participants aged between 25 to 53 years old)
The review found no eligible studies for this question.
1 finding from 1 review
- Immediate‐release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults 2021 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Immediate‐release methylphenidate vs lithium
Anxiety · adults with ADHD (available evidence for participants aged between 25 to 53 years old)
1 finding from 1 review
- Immediate‐release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults 2021 · Cochrane Headline outcomes onlyno estimate extracted1 study · 46 participantsVery low
Immediate‐release methylphenidate vs lithium
Depression: investigator‐rated · adults with ADHD (available evidence for participants aged between 25 to 53 years old)
1 finding from 1 review
- Immediate‐release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults 2021 · Cochrane Headline outcomes onlyno estimate extracted1 study · 46 participantsVery low
Immediate‐release methylphenidate vs lithium
Harms: adverse events (poorly assessed and reported) · adults with ADHD (available evidence for participants aged between 25 to 53 years old)
The review found no eligible studies for this question.
1 finding from 1 review
- Immediate‐release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults 2021 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Immediate‐release methylphenidate vs lithium
ADHD symptoms · adults with ADHD (available evidence for participants aged between 25 to 53 years old)
1 finding from 1 review
- Immediate‐release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults 2021 · Cochrane Headline outcomes onlyno estimate extracted1 study · 46 participantsVery low
Immediate‐release methylphenidate vs lithium
Efficacy (changes in symptoms of ADHD): participant‐rated ‐ not reported · adults with ADHD (available evidence for participants aged between 25 to 53 years old)
The review found no eligible studies for this question.
1 finding from 1 review
- Immediate‐release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults 2021 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found